Roper Technologies (ROP) Receives a Rating Update from a Top Analyst
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Thill covers the Technology sector, focusing on stocks such as Oracle, Microsoft, and Intuit. According to TipRanks, Thill has an average return of 14.9% and a 68.34% success rate on recommended stocks.
In addition to Jefferies, Roper Technologies also received a Buy from Truist Financial's Terry Tillman in a report issued today. However, on July 9, Barclays maintained a Sell rating on Roper Technologies (NASDAQ: ROP).
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ROP in relation to earlier this year. Most recently, in May 2025, Christopher Wright, a Director at ROP sold 350.00 shares for a total of $200,277.00.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Alpha Modus Holdings Inc. (NASDAQ: AMOD) Eliminates Variable Rate Debt and Finalizes Capital Structure Cleanup
CHARLOTTE, N.C., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Modus Holdings Inc. (NASDAQ: AMOD), a pioneer in AI-driven retail technology, is pleased to announce a significant milestone in its ongoing commitment to long-term shareholder value. As of today, the Company confirms that all variable rate debt associated with the DESPAC process has been fully resolved and extinguished. This achievement marks the culmination of a strategic initiative that has been central to Alpha Modus' financial philosophy over the past six months: preserving the integrity of the company's capital structure and avoiding the use of dilutive derivative instruments that erode shareholder confidence. 'We've been very clear with the market—we will not jeopardize our vision or shareholder value through toxic financing,' said William Alessi, CEO of Alpha Modus. 'Today's announcement reflects our steadfast commitment to that principle. We now operate with a fully streamlined capital structure—clear, investor-aligned, and built to support long-term value creation.' With a clean cap table and no third-party variable rate debt overhang, Alpha Modus enters its next phase of expansion with enhanced appeal to institutional investors, strategic partners, and shareholders focused on long-term value creation. For more information, visit: About Alpha Modus Holdings Modus Holdings Inc. (NASDAQ: AMOD) is redefining the retail experience through its patented AI technologies, intelligent kiosks, and targeted consumer engagement tools. By integrating innovation with infrastructure, Alpha Modus is unlocking new monetization pathways for retailers and fintech providers alike. For more information and to access Alpha Modus' press room, visit: Forward-Looking StatementsThis press release includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. Alpha Modus's actual results may differ from their expectations, estimates, and projections, and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as 'expect,' 'estimate,' 'project,' 'budget,' 'forecast,' 'anticipate,' 'intend,' 'plan,' 'may,' 'will,' 'could,' 'should,' 'believes,' 'predicts,' 'potential,' 'continue,' and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements, but are not the exclusive means of identifying these statements. These forward-looking statements include, without limitation, Alpha Modus's expectations with respect to future performance. Alpha Modus cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Alpha Modus does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based. Contact Information Investor RelationsAlpha Modus Holdings, ir@ Follow us on LinkedIn | Follow us on XError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
CareCloud, Inc. (CCLD): A Bull Case Theory
This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return potential, read our free article: 10 Promising SmallCap Stocks Under $1 Billion Market Cap. We came across a bullish thesis on CareCloud, Inc. (CCLD) on Undervalued and undercovered 's Substack by Hugh Navarro. In this article, we will summarize the bulls' thesis on CCLD. CareCloud, Inc. (CCLD)'s share was trading at $2.4 as of 16th July. CCLD's forward P/E was 8.28, respectively according to Yahoo Finance. A doctor utilizing a cloud-based healthcare platform to access patient records. CareCloud (Nasdaq: CCLD) presents a rare opportunity in the healthcare IT sector—a high-margin, recurring-revenue business trading at a deeply discounted valuation with an 18% free cash flow yield. Its core offering is a vertically integrated platform providing Revenue Cycle Management (RCM), Electronic Health Records (EHR), and Practice Management (PM) software to small and medium-sized medical practices. With 67% of revenue from RCM, CareCloud helps practices get paid faster and more efficiently, boasting a denial rate under 3% and up to 94% first-pass claims. The cloud-based system integrates billing, insurance checks, and analytics, differentiating itself with robotic automation and an in-house clearinghouse. Complementing this is a growing AI layer, cirrusAI, which powers real-time clinical note generation, chatbot support for staff, and automated appeals for denied claims. The company is aggressively expanding this AI infrastructure, aiming for 500 engineers by year-end, setting it up for long-term product superiority. Despite an 11% contribution from medical practice management, the real upside lies in the company's scalable tech and a consolidation strategy focused on acquiring customer bases from smaller, less efficient players. CareCloud also benefits from significant NOLs, insulating it from taxes for years. Past selling pressure due to a complex preferred-share structure has left shares undervalued, but a founder-led, 15%-insider-owned management team is now aligned for growth. The sector's rising complexity and demand for automation make CareCloud's solutions increasingly vital. With churn at just 5%, strong embedded pricing power, and multiple growth levers, the stock offers a compelling path to multi-bagger returns, potentially 5x from current levels. Previously we covered a on SANUWAVE Health, Inc. (SNWV) by @rationalformula in May 2025, which highlighted the company's turnaround story, recurring revenue from its FDA-cleared wound care device, and strong operational momentum. The company's stock price has appreciated by approximately 7% since our coverage. This is because the thesis played out with improving financials and execution. This is because demand for its consumables remains strong despite historical challenges. CareCloud author shares a similar view but emphasizes on software-driven efficiency and AI-powered automation as the growth engine in healthcare IT. CareCloud, Inc. (CCLD) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 3 hedge fund portfolios held CCLD at the end of the first quarter which was 3 in the previous quarter. While we acknowledge the potential of CCLD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
11 minutes ago
- Business Wire
Vistagen to Present at the BTIG Virtual Biotechnology Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, July 29, at 10 a.m. Eastern Time. The Fireside Chat will be livestreamed for registered investors, and a recording will be available on the BTIG conference portal for conference attendees following the event. If you would like to schedule a one-on-one meeting with Vistagen's management team, please contact your BTIG representative. To join the conference, email uscorporateaccess@ About Vistagen Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to rapidly activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. They are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options if successfully developed and approved. Vistagen is passionate about developing transformative treatment options to improve the lives of individuals underserved by the current standard of care for multiple highly prevalent indications, including social anxiety disorder, major depressive disorder, and multiple women's health conditions, such as vasomotor symptoms (hot flashes) associated with menopause. Connect at
